Molecular Subtyping for Prognosis Evaluation in Resected Pancreatic Adenocarcinoma

BAIYONG SHEN226 enrolled

Overview

Pancreatic adenocarcinoma (PAAD) patients following surgeries are prone to relapse shortly, while it is not well understood by current biomarkers. Given the potential associations of human leukocyte antigen class I (HLA-I) genotype with oncogenic mutational profile and immunotherapy efficacy, we aimed to assess whether differential HLA-I genotype could predict the postoperative outcomes in resected PAAD patients.

Study Type

OBSERVATIONAL

Enrollment

226

Conditions

Pancreatic Cancer Resectable

Interventions

Multigene panel for next-generation sequencingDEVICE

HLA-I genotyping based on next-generation sequencing for prognosis evaluation

Eligibility

Sex: ALLMin age: 34 YearsMax age: 84 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Radically resected pancreatic adenocarcinoma (stage I-III) * Resected tumor tissues and matched blood cells available * Signed informed consent Exclusion Criteria: * Pancreatic cancer except pancreatic adenocarcinoma * Non-radical resection

Locations (1)

Ruijin Hospital

Shanghai, Shanghai Municipality, China

Outcomes

Primary Outcomes

Disease-free survival (DFS)

Comparison of DFS between patients with specific HLA-I genotypes or not

Time frame: 2 years

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.